Head-to-head evidence
Dorzagliatin vs HMS1005
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Glucokinase · full Type 2 Diabetes pipeline
Dorzagliatin · Huatangning
Developed by Hua Medicine
NCT04531631 · Phase 2 · completed
The study used randomized, triple-blind, placebo-controlled crossover treatment, but enrolled only 18 participants and measured a mechanistic insulin-response biomarker rather than a clinical diabetes outcome. Because the registry provides no primary-endpoint results, it is not possible to determine whether the comparison met its prespecified endpoint.
Next expected readout: March 2029 · NCT07786571 (registry estimate)
HMS1005
Developed by Hua Medicine
NCT06498284 · Phase 1 · completed
The trial randomized participants against a matched placebo with both participants and investigators blinded, but the primary measures were safety and drug levels rather than a validated diabetes outcome like HbA1c. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The sponsor release does not cite the trial's registry number; identity rests on the matching sponsor, drug code, country, design and enrollment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dorzagliatin's landscape · HMS1005's landscape